{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:38:41Z","timestamp":1759451921098,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.humimm.2025.111329","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T11:01:22Z","timestamp":1746788482000},"page":"111329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["IL17RA genetic variants are associated with susceptibility and severity of psoriasis"],"prefix":"10.1016","volume":"86","author":[{"given":"Camila Cataldi","family":"de Alcantara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edna Maria","family":"Vissoci Reiche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8781-1505","authenticated-orcid":false,"given":"C\u00e1ssio Rafael","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamires Flauzino","family":"Luz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ligia M\u00e1rcia","family":"M\u00e1rio Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcell Alysson","family":"Batisti Lozovoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9a Name","family":"Colado Sim\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humimm.2025.111329_b0005","first-page":"18","article-title":"Psoriasis risk factors and triggers","volume":"102","author":"Lee","year":"2018","journal-title":"Cutis"},{"key":"10.1016\/j.humimm.2025.111329_b0010","doi-asserted-by":"crossref","unstructured":"Kamiya, K. Kishimoto, M. Sugai, J. Komine, M. Ohtsuki, M. Risk Factors for the Development of Psoriasis. Int J Mol Sci. 0291; 20:4347. doi: 10.3390\/ijms20184347.","DOI":"10.3390\/ijms20184347"},{"key":"10.1016\/j.humimm.2025.111329_b0015","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5114\/reum.2022.120752","article-title":"The role of HLA-Cw6 in psoriasis and psoriatic arthritis","volume":"60","author":"Owczarek","year":"2022","journal-title":"Reumatologia"},{"key":"10.1016\/j.humimm.2025.111329_b0020","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.3390\/ijms23136955","article-title":"Roles of Infection in Psoriasis","volume":"23","author":"Zhou","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.humimm.2025.111329_b0025","first-page":"87","article-title":"Drug-induced psoriasis: clinical perspectives","author":"Balak","year":"2017","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.humimm.2025.111329_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.880201","article-title":"Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review","volume":"13","author":"Bu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2025.111329_b0035","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s12325-020-01346-6","article-title":"Psoriasis and Cardiovascular Risk: A Comprehensive Review","volume":"37","author":"Masson","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.humimm.2025.111329_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2021.101670","article-title":"Clinical features of psoriatic arthritis","volume":"35","author":"Kishimoto","year":"2021","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.humimm.2025.111329_b0045","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 family of cytokines in psoriasis: IL-17A and beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2025.111329_b0050","doi-asserted-by":"crossref","first-page":"6740","DOI":"10.3390\/ijms22136740","article-title":"From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment","volume":"22","author":"Vidal","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.humimm.2025.111329_b0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/09546634.2013.879093","article-title":"The role of IL-17 in psoriasis","volume":"26","author":"Malakouti","year":"2015","journal-title":"J. Dermatolog. Treat."},{"key":"10.1016\/j.humimm.2025.111329_b0060","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00403-012-1229-1","article-title":"Serum and tissue levels of IL17 in different clinical subtypes of psoriasis","volume":"304","author":"Yilmaz","year":"2012","journal-title":"Archiv Dermatol Res."},{"key":"10.1016\/j.humimm.2025.111329_b0065","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2133.2008.08902.x","article-title":"Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin","volume":"160","author":"Johansen","year":"2009","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.humimm.2025.111329_b0070","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1177\/1203475416651605","article-title":"The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis","volume":"20","author":"AbuHilal","year":"2016","journal-title":"J. Cutan. Med. Surg."},{"key":"10.1016\/j.humimm.2025.111329_b0075","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.3390\/jcm10245834","article-title":"An Analysis ofIL-10,IL-17A,IL-17RA,IL-23AandIL-23RExpression and Their Correlation with Clinical Course in Patients with Psoriasis","volume":"10","author":"Kutwin","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.humimm.2025.111329_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.621956","article-title":"Major Role of the IL17\/23 Axis in Psoriasis Supports the Development of New Targeted Therapies","volume":"12","author":"Bugaut","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2025.111329_b0085","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.3390\/ijms22094983","article-title":"Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics","volume":"22","author":"Petit","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.humimm.2025.111329_b0090","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/bjd.20090","article-title":"Signalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor A drives psoriasis-related inflammatory pathways","volume":"185","author":"Tollenaere","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2025.111329_b0095","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-018-0888-4","article-title":"Brodalumab: a review in moderate to severe plaque psoriasis","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.humimm.2025.111329_b0100","article-title":"Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study\u2014IL PSO (Italian landscape psoriasis)","volume":"10","author":"Gargiulo","year":"2023","journal-title":"Front. Med.2"},{"key":"10.1016\/j.humimm.2025.111329_b0105","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00011-019-01238-8","article-title":"Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors","volume":"68","author":"Cataldi","year":"2019","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.humimm.2025.111329_b0110","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/bs.acc.2020.04.004","article-title":"Cytokines in psoriasis","volume":"100","author":"de Alcantara","year":"2021","journal-title":"Adv. Clin. Chem."},{"key":"10.1016\/j.humimm.2025.111329_b0115","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.molimm.2023.05.010","article-title":"IL36G genetic variant is independently associated with susceptibility, severity and joint involvement in psoriasis","volume":"159","author":"de Moreira","year":"2023","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.humimm.2025.111329_b0120","doi-asserted-by":"crossref","unstructured":"Batalla, A. Coto, E. G\u00f3mez, J. Eir\u00eds, N. Gonz\u00e1lez-Fern\u00e1ndez, D. G\u00f3mez-De Castro, C. Daud\u00e9n, E. Llamas-Velasco, M. Prieto-Perez, R. Abad-Santos, F. Carretero, G. Garc\u00eda, F.S. Godoy, Y.B. Cardo, L.F. Alonso, B. Iglesias, S. Coto-Segura, P. IL17RA gene variants and anti-TNF response among psoriasis patients. Pharmacogenomics J. 2018; 18:76-80. doi: 10.1038\/tpj.2016.70.","DOI":"10.1038\/tpj.2016.70"},{"key":"10.1016\/j.humimm.2025.111329_b0125","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00011-021-01514-6","article-title":"Association between IL-17A, IL-17F and IL-17RA gene polymorphisms and susceptibility to psoriasis and psoriatic arthritis: a meta-analysis","volume":"70","author":"Villalpando-Vargas","year":"2021","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.humimm.2025.111329_b0130","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00296-012-2501-6","article-title":"IL-23A, IL-23R, IL-17A and IL-17R polymorphisms in different psoriatic arthritis clinical manifestations in the northern Italian population","volume":"33","author":"Catanoso","year":"2013","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.humimm.2025.111329_b0135","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00403-019-02011-x","article-title":"potential association between psoriasin to rs4819554 of IL-17RA gene polymorphism in psoriasis Egyptian patients","volume":"312","author":"Sabry","year":"2020","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.humimm.2025.111329_b0140","article-title":"Association between IL-17F, IL-17RA Gene Polymorphisms and response to biological drugs in psoriasis and beyond","volume":"14(5):1123","author":"Pu\u0219ca\u0219","year":"2023","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.humimm.2025.111329_b0145","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/cei.12888","article-title":"A preliminary study of new single polymorphisms in the T helper type 17 pathway for psoriasis in the Korean population","volume":"187","author":"Kim","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.humimm.2025.111329_b0150","doi-asserted-by":"crossref","unstructured":"Romiti R, Carvalho AVE, Duarte GV; Grupo de Trabalho do Consenso Brasileiro de Psor\u00edase da Sociedade Brasileira de Dermatologia. Brazilian Consensus on Psoriasis 2020 and Treatment Algorithm of the Brazilian Society of Dermatology. Ann Bras Dermatol. 2021; 96:778-781. doi: 10.1016\/j.abd.2021.03.007.","DOI":"10.1016\/j.abd.2021.03.007"},{"key":"10.1016\/j.humimm.2025.111329_b0155","doi-asserted-by":"crossref","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med. 376 (2017) 957-970. doi: 10.1056\/NEJMra1505557. Erratum in: N Engl J Med. 2017; 376:2097.","DOI":"10.1056\/NEJMra1505557"},{"key":"10.1016\/j.humimm.2025.111329_b0160","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/0962280217737157","article-title":"Power and sample size for multivariate logistic modeling of unmatched case-control studies","volume":"28","author":"Gail","year":"2019","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.humimm.2025.111329_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mgene.2015.04.003","article-title":"Genetic model selection for a case-control study and a meta-analysis","volume":"22","author":"Horita","year":"2015","journal-title":"Meta Gene."},{"key":"10.1016\/j.humimm.2025.111329_b0170","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/bioinformatics\/btl268","article-title":"SNPStats: a web tool for the analysis of association studies","volume":"22","author":"Sol\u00e9","year":"2006","journal-title":"Bioinformatics"},{"key":"10.1016\/j.humimm.2025.111329_b0175","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1186\/s13075-014-0426-z","article-title":"Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?","volume":"16","author":"van Baarsen","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.humimm.2025.111329_b0180","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jaci.2019.10.041","article-title":"Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis","volume":"145","author":"Tomalin","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.humimm.2025.111329_b0185","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12881-020-01078-y","article-title":"Copy number variation of IL17RA gene and its association with the ankylosing spondylitis risk in Iranian patients: a case-control study","volume":"21","author":"Aghaei","year":"2020","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.humimm.2025.111329_b0190","article-title":"Cumulative evidence for associations between genetic variants in interleukin 17 family gene and risk of human diseases","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2025.111329_b0195","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/15476286.2023.2223486","article-title":"Implications of LncRNAs and CircRNAs in psoriasis: a review","volume":"20","author":"Shi","year":"2023","journal-title":"RNA Biol."},{"key":"10.1016\/j.humimm.2025.111329_b0200","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.3390\/biomedicines10081934","article-title":"Contribution of the Environment, Epigenetic Mechanisms and Non-Coding RNAs in Psoriasis","volume":"10","author":"Antonatos","year":"2022","journal-title":"Biomedicines.2"},{"key":"10.1016\/j.humimm.2025.111329_b0205","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bjd.12001","article-title":"Interactions between adiposity and genetic polymorphisms on the risk of psoriasis","volume":"168","author":"Li","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2025.111329_b0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002739","article-title":"Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study","volume":"16","author":"Budu-Aggrey","year":"2019","journal-title":"PLoS Med."}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885925001004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885925001004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:15:35Z","timestamp":1759400135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0198885925001004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0198885925001004"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2025.111329","relation":{},"ISSN":["0198-8859"],"issn-type":[{"type":"print","value":"0198-8859"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL17RA genetic variants are associated with susceptibility and severity of psoriasis","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2025.111329","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111329"}}